申请人:Warner-Lambert Company
公开号:US04521416A1
公开(公告)日:1985-06-04
4,5-Dihydro-6-[(substituted)-1H-imidazol-4-yl or 5-yl]-3(2H)-pyridazinones 6-[(substituted)-1H- imidazol-4-yl or 5-yl]-3(2H)-pyridazinones and pharmaceutically acceptable acid addition salts thereof are useful as cardiotonic and antihypertensive agents. The above compounds cause a significant increase in myocardial contractility in the dog and also cause a decrease in blood pressure in the spontaneously hypertensive rat. The compounds are produced by reacting the appropriate .gamma.-oxo-imidazolebutanoic acid with a suitably substituted hydrazine to provide 4,5-dihydro-6-(substituted)imidazolyl-3(2H)-pyridazinones which are oxidized to 6-(substituted)imidazolyl-3(2H)-pyridazinones.
4,5-二氢-6-[(取代基)-1H-咪唑-4-基或5-基]-3(2H)-吡啶嗪酮6-[(取代基)-1H-咪唑-4-基或5-基]-3(2H)-吡啶嗪酮及其药学上可接受的酸加合物可作为心力衰竭和抗高血压药物。以上化合物可导致狗的心肌收缩力显著增强,并可导致自发性高血压大鼠的血压降低。所述化合物是通过将适当的γ-氧代咪唑丁酸与适当取代的肼反应而制得的,从而得到4,5-二氢-6-(取代)咪唑基-3(2H)-吡啶嗪酮,其被氧化为6-(取代)咪唑基-3(2H)-吡啶嗪酮。